epoetin alfa

epoetin alfa
Name	Epoetin alfa

epoetin alfa is a recombinant Human Genome Sciences-derived version of erythropoietin, a glycoprotein hormone produced by the kidney. It is used to treat anemia resulting from chronic kidney disease, HIV infection, and cancer chemotherapy, as well as to reduce the need for blood transfusion in patients undergoing surgery at Johns Hopkins Hospital or Massachusetts General Hospital. The development of epoetin alfa was a major breakthrough in the field of hematology, with significant contributions from researchers at Harvard University, Stanford University, and the National Institutes of Health.

Introduction

Epoetin alfa is produced through recombinant DNA technology by Amgen, a leading biotechnology company, in collaboration with University of California, Los Angeles and University of California, San Francisco. It is marketed under the brand name Epogen by Amgen and Procrit by Ortho Biotech, a subsidiary of Johnson & Johnson, with significant distribution partnerships with Pfizer, Merck & Co., and GlaxoSmithKline. The introduction of epoetin alfa has revolutionized the treatment of anemia in patients with chronic kidney disease, as seen in studies conducted at Columbia University and University of Pennsylvania. Researchers at Duke University and University of Chicago have also explored its potential applications in oncology and cardiology.

Medical Uses

Epoetin alfa is used to treat anemia resulting from chronic kidney disease, HIV infection, and cancer chemotherapy, as well as to reduce the need for blood transfusion in patients undergoing surgery at Mayo Clinic or Cleveland Clinic. It is also used to treat anemia in patients with HIV infection receiving antiretroviral therapy at University of California, San Diego or University of Washington. The medical uses of epoetin alfa have been extensively studied by researchers at University of Oxford, University of Cambridge, and Karolinska Institutet, with significant contributions from World Health Organization and National Cancer Institute.

Mechanism of Action

Epoetin alfa works by stimulating the production of red blood cells in the bone marrow, a process regulated by transcription factors and signaling pathways studied at Massachusetts Institute of Technology and California Institute of Technology. It binds to the erythropoietin receptor on the surface of red blood cell precursors, activating a signal transduction pathway that promotes cell survival and proliferation, as described in research papers published in Nature and Science. This process is mediated by Janus kinase 2 and signal transducer and activator of transcription proteins, which are also involved in immune response and inflammation pathways studied at University of Toronto and University of Melbourne.

Side Effects

The side effects of epoetin alfa include headache, fatigue, nausea, and vomiting, as well as more serious adverse effects such as thrombosis and hypertension, which have been reported in studies conducted at University of California, Berkeley and University of Michigan. Patients receiving epoetin alfa should be monitored for signs of allergic reaction, such as anaphylaxis, and immune response to the drug, as recommended by Food and Drug Administration and European Medicines Agency. Researchers at University of Edinburgh and University of Sydney have also investigated the potential risks of epoetin alfa in patients with chronic kidney disease and cancer.

History

The development of epoetin alfa began in the 1980s, when researchers at University of California, Los Angeles and Amgen isolated the gene for erythropoietin and developed a method for producing the protein using recombinant DNA technology, with significant contributions from National Science Foundation and Howard Hughes Medical Institute. The first clinical trials of epoetin alfa were conducted in the late 1980s, and the drug was approved for use in the United States by the Food and Drug Administration in 1989, with subsequent approvals in Europe and Japan by European Medicines Agency and Pharmaceuticals and Medical Devices Agency. The history of epoetin alfa has been documented in research papers published in New England Journal of Medicine and Lancet.

Chemistry

Epoetin alfa is a glycoprotein hormone composed of 165 amino acid residues, with a molecular weight of approximately 30,000 daltons, as determined by researchers at University of California, San Francisco and Stanford University. It is produced through recombinant DNA technology in Chinese hamster ovary cells, which are engineered to express the gene for erythropoietin, as described in research papers published in Journal of Biological Chemistry and Biochemistry. The chemical structure of epoetin alfa has been studied extensively by researchers at University of Cambridge and University of Oxford, with significant contributions from Wellcome Trust and Bill and Melinda Gates Foundation.

Category:Recombinant proteins